Array BioPharma (ARRY) : 8 brokerage houses believe that Array BioPharma (ARRY) is a Strong Buy at current levels. Zacks Investment Research suggests a Hold with a rank of 3.The median of all the 8 Wall Street Analysts endorse the stock as a Strong Buy with a rating of 1.
Array BioPharma (ARRY) : The most positive equity analysts on Array BioPharma (ARRY) expects the shares to touch $13, whereas, the least positive believes that the stock will trade at $7 in the short term. The company is covered by 6 Wall Street Brokerage Firms. The average price target for shares are $8.67 with an expected fluctuation of $2.25 from the mean.
For the current week, the company shares have a recommendation consensus of Buy. Array BioPharma (NASDAQ:ARRY): During Thursdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $3.50 and $3.38 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $3.56. The buying momentum continued till the end and the stock did not give up its gains. It closed at $3.52, notching a gain of 0.57% for the day. The total traded volume was 1,887,805 . The stock had closed at $3.50 on the previous day.
In a related news, The Securities and Exchange Commission has divulged that Baum Charles M, director of Array Biopharma Inc, had unloaded 25,000 shares at an average price of $7.38 in a transaction dated on May 8, 2015. The total value of the transaction was worth $184,500.
Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule drugs to treat patients afflicted with cancer. The Companys wholly owned clinical stage drugs include Filanesib in Phase II clinical trials, is indicated for Kinesin spindle protein (KSP), inhibitor for MM; ARRY-797 in Phase II clinical trials, indicated for p38 inhibitor for Lamin A/C-related dilated cardiomyopathy (LMNA-DCM); ARRY-502 in Phase II clinical trials, indicated for CRTh2 antagonist for asthma, and ARRY-614 in Phase I clinical trials, is indicated for p38/Tie2 dual inhibitor for myelodysplastic syndromes (MDS). In addition, the Company has 11 ongoing partner-funded clinical programs, including two MEK inhibitors, which are both in Phase III clinical trials, binimetinib with Novartis and selumetinib with AstraZeneca.